The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

bufomedil     4-pyrrolidin-1-yl-1-(2,4,6...

Synonyms: Buflomedil, blufomedil, Buflomedilum, CHEMBL188921, SureCN150905, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Buflomedil


Psychiatry related information on Buflomedil

  • The pharmacological effects of buflomedil in patients with multi-cerebral infarcts dementia: an open, preliminary assessment [5].
  • In conclusion, buflomedil is as effective or more effective than dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency and could prove a valuable addition to long-term therapy if further studies support the trend shown in this study [6].
  • Psychometric investigations demonstrated that after 50 mg buflomedil i.v. there was a significant improvement as compared with placebo in cognitive function based on the Pauli test as well as an increase in correct reactions in the alphabetical reaction test [7].
  • The efficacy of buflomedil was monitored using rating scales and neuropsychological tests [8].
  • Compared with placebo, buflomedil showed a clear superiority with regard to improvement in cognitive dysfunction and psychosomatic dysfunction, with a trend toward statistical significance in improvement in interpersonal relations [9].

High impact information on Buflomedil


Chemical compound and disease context of Buflomedil


Biological context of Buflomedil


Anatomical context of Buflomedil


Associations of Buflomedil with other chemical compounds


Gene context of Buflomedil

  • The activity of three enzymes was measured (acetylcholinesterase - Ache, dehydrogenase glucoso-6-phosphate - G-6-PD and gluthatione reductase - GR) for both bfl and TCDD-treated RBC [27].
  • Buflomedil (except at supra-therapeutic concentrations) exerted no effect on endothelin release by HUVECS [28].
  • Experience with buflomedil in peripheral arterial occlusive disease [29].
  • In vitro incubation of PRP with buflomedil in concentrations above 10 mumol/l resulted in a significant depression of PA to approximately one-third of the control [30].
  • Buflomedil dosage was elevated to 6.3 mg/l (N = 4-4.5 mg/l) [31].

Analytical, diagnostic and therapeutic context of Buflomedil


  1. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Clissold, S.P., Lynch, S., Sorkin, E.M. Drugs (1987) [Pubmed]
  2. Anaphylactic reactions to buflomedil. Scala, E., Guerra, E.C., Pirrotta, L., Giani, M., De Pità, O., Puddu, P. Allergy (1999) [Pubmed]
  3. Effects of buflomedil and its two derivatives, CRL40634 and CRL40598, on pancreatic exocrine secretion in the rat. Chariot, J., Nagain, C., Vaille, C., Rozé, C. Eur. J. Pharmacol. (1990) [Pubmed]
  4. Buflomedil hydrochloride reduces systemic activation of polymorphonuclear leukocytes during hyperdynamic endotoxemia. Holzer, K., Thiel, M., Kreimeier, U., Moritz, S., Messmer, K. Shock (1998) [Pubmed]
  5. The pharmacological effects of buflomedil in patients with multi-cerebral infarcts dementia: an open, preliminary assessment. Karoutas, G., Milonas, I., Artemis, N., Karacostas, D., Pitas, J., Logothetis, J. Current medical research and opinion. (1987) [Pubmed]
  6. The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids. Jansen, W., Bruckner, G.W., Jansen, P. J. Int. Med. Res. (1985) [Pubmed]
  7. Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: double-blind, placebo-controlled pharmaco-EEG and psychometric studies. Saletu, B., Grünberger, J., Linzmayer, L., Stöhr, H. International journal of clinical pharmacology research. (1984) [Pubmed]
  8. Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin. Cucinotta, D., Aveni Casucci, M.A., Pedrazzi, F., Ponari, O., Capodaglio, M., Valdina, P., Toxiri, I., Bartorelli, L., Granata, Q., Franzini, C. J. Int. Med. Res. (1992) [Pubmed]
  9. Effect of buflomedil on behaviour, memory, and intellectual capacity in patients with dementia. A placebo-controlled study. Levinson, B., Wright, P., Barklem, S. S. Afr. Med. J. (1985) [Pubmed]
  10. Pretreatment with buflomedil enhances ventricular function by reducing the dysfunctional area after transient coronary artery occlusion. Weinheimer, C.J., Toeniskoetter, P.D., Conversano, A., Pelat, P., Dubourg, A.Y., Bergmann, S.R. Cardiovasc. Res. (1992) [Pubmed]
  11. Buflomedil concentrations in blood and viscera in a case of fatal intoxication. Athanaselis, S., Maravelias, C., Michalodimitrakis, M., Koutselinis, A. Clin. Chem. (1984) [Pubmed]
  12. Effects of torbafylline, pentoxifylline and buflomedil on vascularisation and fibre type of rat skeletal muscles subjected to limited blood supply. Hudlická, O., Price, S. Br. J. Pharmacol. (1990) [Pubmed]
  13. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. Rosas, G., Cerdeyra, C., Lucas, M.A., Parano, J.R., Villa, J.J. Angiology. (1981) [Pubmed]
  14. Inhibitory effect of buflomedil on prostate alpha1A adrenoceptor in the Wistar rat. Tang, L.M., Cheng, J.T., Tong, Y.C. Neurosci. Lett. (2004) [Pubmed]
  15. The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration. Gundert-Remy, U., Weber, E., Lam, G., Chiou, W.L., Mann, W., Aynilian, G.H. Eur. J. Clin. Pharmacol. (1981) [Pubmed]
  16. Increase in plasma levels of adenosine and adenine nucleotides after intravenous infusion of buflomedil in humans. Capecchi, P.L., Laghi Pasini, F., Sodi, N., Chiavetta, M., Sensi, S., De Lalla, A., Volpi, L., Di Perri, T. J. Cardiovasc. Pharmacol. (1995) [Pubmed]
  17. The influence of buflomedil on blood viscosity parameters in insulin-dependent diabetic patients: a preliminary study. Van Acker, K., Rillaerts, E., De Leeuw, I. Biomed. Pharmacother. (1989) [Pubmed]
  18. An evaluation of the ability of the peripheral vasodilator buflomedil to improve vascular patency after acute frostbite. Daum, P.S., Bowers, W.D., Tejada, J., Morehouse, D., Hamlet, M.P. Cryobiology (1989) [Pubmed]
  19. Effects of buflomedil on the responsiveness of canine vascular smooth muscle. Vanhoutte, P.M., Aarhus, L.L., Coen, E., Lorenz, R.R., Rimele, T.J., Verbeuren, T.J. J. Pharmacol. Exp. Ther. (1983) [Pubmed]
  20. Improvement of microcirculation abnormalities in sickle cell patients upon buflomedil treatment. Bachir, D., Maurel, A., Beuzard, Y., Razavian, M., Kraiem, A., Portos, J.L., Galacteros, F. Microvasc. Res. (1993) [Pubmed]
  21. Haemodynamic and haemorheological effects of buflomedil in patients with peripheral occlusive arterial disease. Perego, M.A., Sergio, G., Espureo, M., Francisci, A., Artale, F. Current medical research and opinion. (1982) [Pubmed]
  22. Effect of buflomedil (4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxy phenyl)-1-butanone hydrochloride) on the function of striatal dopaminergic neurons. Koda, H., Hashimoto, T., Kuriyama, K. Jpn. J. Pharmacol. (1989) [Pubmed]
  23. Determination of buflomedil hydrochloride [2',4',6'-trimethoxy-4-(pyrrolidinyl)butyrophenone hydrochloride] by reversed-phase ion-pair high-performance liquid chromatography. Badmin, J.A., Kumar, J.L., Mann, W.C. J. Chromatogr. (1979) [Pubmed]
  24. Vasoactive effects of buflomedil assessed by fluorescein angiography. Platania, A., Sciuto, V., De Martino Rosaroll, G. Current medical research and opinion. (1987) [Pubmed]
  25. Effect of buflomedil on the neutrophil-endothelial cell interaction under inflammatory and hypoxia conditions. Boisseau, M.R., Pruvost, A., Renard, M., Closse, C., Belloc, F., Seigneur, M., Maurel, A. Haemostasis (1996) [Pubmed]
  26. Effect of buflomedil [4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone hydrochloride] on neurotransmitters in the striatum and substantia nigra. Koda, H., Hashimoto, T., Kuriyama, K. Jpn. J. Pharmacol. (1988) [Pubmed]
  27. Rheological and biochemical examination of red blood cells after treatment with different pharmacological and toxic substances. Nowak, E., Wyrwicz, G., Dabrowski, Z., Smolenski, O., Spodaryk, K. Clin. Hemorheol. Microcirc. (2002) [Pubmed]
  28. Effect of buflomedil on in vitro prostacyclin and endothelin synthesis by vascular (rat and human) and penile (rat) tissue and calcium uptake by isolated human platelets. Jeremy, J.Y., Gill, J., DuBourg, A., Pelat, P., Mikhailidis, D.P. Int. J. Impot. Res. (1993) [Pubmed]
  29. Experience with buflomedil in peripheral arterial occlusive disease. Balas, P., Pagratis, N. Angiology. (1981) [Pubmed]
  30. Effect of buflomedil on epinephrine-enhanced platelet aggregation in vitro and ex vivo. Wurzinger, L.J., Schmid-Schönbein, H. Arzneimittel-Forschung. (1987) [Pubmed]
  31. Warning! One buflomedil may hide another one! Chiffoleau, A., Yatim, D., Garrec, F., Veyrac, G., Raoult, P., Larousse, C., Bourin, M. Thérapie. (2000) [Pubmed]
  32. Analysis of buflomedil in mouse, rat and rabbit plasma by reversed-phase ion-pair high-performance liquid chromatography. Thomas, E.W. J. Chromatogr. (1982) [Pubmed]
  33. Buflomedil is a potent interfering substance in immunoassays of tricyclic antidepressants. Mura, P., Kintz, P., Robert, R., Papet, Y. Journal of analytical toxicology. (1998) [Pubmed]
  34. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Walker, G.A., Mac Hannaford, J.C. Fundamental & clinical pharmacology. (1995) [Pubmed]
WikiGenes - Universities